| Not Yet Recruiting | Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer NCT07537946 | Tongji Hospital | Phase 3 |
| Not Yet Recruiting | Exercise Training in Women With Metastatic Breast Cancer NCT07521826 | State University of Londrina | N/A |
| Recruiting | Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroeso NCT07176312 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Not Yet Recruiting | High Dose Radiotherapy for Palliation (Hi-D) NCT07291895 | British Columbia Cancer Agency | N/A |
| Not Yet Recruiting | SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors NCT06937281 | British Columbia Cancer Agency | N/A |
| Not Yet Recruiting | EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Senti NCT07018505 | Yunnan Cancer Hospital | — |
| Recruiting | Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Meta NCT06713161 | Yunnan Cancer Hospital | — |
| Recruiting | Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease NCT06356779 | Gitte Fredberg Persson MD PhD | N/A |
| Recruiting | Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Co NCT05195710 | M.D. Anderson Cancer Center | Phase 1 |
| Unknown | Liver Transplantation for Unresectable GIST Liver Metastases NCT04825470 | Hospital Universitario Virgen de la Arrixaca | N/A |
| Unknown | Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM NCT05136768 | Jun-Lin Yi, MD | Phase 2 |
| Unknown | 68Ga-PSMA PET in the Prostate Cancer NCT04967001 | Xijing Hospital | N/A |
| Recruiting | 68Ga-PSMA PET in the Renal Cell Carcinoma NCT04987086 | Xijing Hospital | N/A |
| Unknown | Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment NCT04066322 | Fudan University | — |
| Completed | CE-IOUS Impact on Surgical Strategy of Liver Tumours and Liver Metastases NCT05261113 | University of Regensburg | — |
| Withdrawn | Whole-body MRI for the Detection of Metastasis NCT02183597 | Norwegian University of Science and Technology | — |
| Unknown | Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER) NCT02452294 | University Hospital Tuebingen | Phase 2 |
| Active Not Recruiting | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Sur NCT02414269 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | S-1 Versus Capecitabine in the First Line Treatment of MCC Patients. NCT01918852 | Dutch Colorectal Cancer Group | Phase 3 |
| Unknown | Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases NCT02301858 | Janna Berg | N/A |
| Completed | Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors NCT02156700 | University Hospital Dubrava | — |
| Unknown | Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial NCT02036008 | Sunnybrook Health Sciences Centre | N/A |
| Terminated | Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer NCT01759238 | Universitätsklinikum Hamburg-Eppendorf | Phase 2 |
| Completed | Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumo NCT01844661 | Hospital Infantil Universitario Niño Jesús, Madrid, Spain | Phase 1 / Phase 2 |
| Completed | Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors NCT01678664 | Federation Francophone de Cancerologie Digestive | Phase 2 |
| Terminated | Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid NCT01403324 | Gustave Roussy, Cancer Campus, Grand Paris | N/A |
| Active Not Recruiting | Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence NCT01442246 | UNICANCER | Phase 3 |
| Completed | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas NCT01231347 | NantCell, Inc. | Phase 3 |
| Completed | Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer NCT01325142 | University of Michigan | — |
| Withdrawn | Surgery and Whole Brain Radiotherapy (RT) Versus Whole Brain Radiotherapy (RT) and Radiosurgery for 1-3 Resect NCT01169129 | Barretos Cancer Hospital | Phase 3 |
| Completed | Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT NCT01213758 | University of Aarhus | — |
| Completed | Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer NCT01091168 | Pierre Fabre Medicament | Phase 3 |
| Completed | Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer NCT00807859 | Amgen | Phase 1 |
| Terminated | Analysis of Tokuhashi Score NCT01210508 | State University of New York - Upstate Medical University | — |
| Completed | AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial O NCT00770536 | Amgen | Phase 1 |
| Completed | A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjec NCT00752570 | Amgen | Phase 2 |
| Completed | Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton NCT00748046 | Bayer | Phase 1 |
| Completed | Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid NCT00569036 | Bristol-Myers Squibb | Phase 1 |
| Terminated | A Phase I/II Dose Escalation Study Using Extracranial Stereotactic Radiosurgery to Control Pain NCT00802659 | Washington University School of Medicine | N/A |
| Completed | PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) NCT00446446 | Amgen | Phase 2 |
| Terminated | Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement NCT00537823 | Washington University School of Medicine | Phase 2 |
| Completed | Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Ch NCT00305188 | Sanofi | Phase 3 |
| Completed | Interferon-Beta Gene Transfer (Ad.hIFN-β) as Treatment for Refractory Colorectal Carcinoma With Liver Metastas NCT00107861 | Biogen | Phase 1 / Phase 2 |
| Terminated | Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer NCT00320320 | Gachon University Gil Medical Center | Phase 2 |
| Terminated | Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer NCT00265200 | University of Louisville | Phase 2 |
| Terminated | Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma NCT00102024 | Biogen | Phase 1 / Phase 2 |
| Terminated | Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) NCT00100685 | Abbott | Phase 2 |
| Completed | Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemothe NCT00099970 | PDL BioPharma, Inc. | Phase 2 |
| Completed | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants Wi NCT00093080 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refra NCT00083720 | Eli Lilly and Company | Phase 2 |
| Completed | MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unres NCT00094653 | Bristol-Myers Squibb | Phase 3 |
| Completed | Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer NCT00091832 | Amgen | Phase 2 |
| Completed | Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer NCT00089635 | Amgen | Phase 2 |
| Terminated | DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer NCT00099281 | YM BioSciences | Phase 3 |
| Completed | Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer NCT00095108 | ZymoGenetics | Phase 1 |
| Completed | Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer NCT00081796 | Sanofi | Phase 3 |
| Completed | A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell NCT00081614 | Genentech, Inc. | Phase 2 |
| Completed | BMS-599626 in Patients With Advanced Solid Malignancies NCT00095537 | Bristol-Myers Squibb | Phase 1 |
| Completed | Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients NCT00080197 | Eisai Inc. | Phase 2 |
| Completed | Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast C NCT00083304 | Spectrum Pharmaceuticals, Inc | Phase 3 |
| Completed | Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC) NCT00080262 | R-Pharm | Phase 2 |
| Completed | Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metast NCT00113763 | Amgen | Phase 3 |
| Completed | Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer NCT00080301 | R-Pharm | Phase 3 |
| Completed | Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma NCT00093119 | Celgene | Phase 2 |
| Completed | A Research Study for Patients With Prostate Cancer NCT00106418 | Celgene | Phase 2 |
| Completed | Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer NCT00313872 | Samsung Medical Center | Phase 3 |
| Completed | A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study NCT00096967 | Genentech, Inc. | Phase 3 |
| Completed | XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Ch NCT00272051 | Sanofi | Phase 3 |
| Completed | A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a NCT00097487 | Genentech, Inc. | — |
| Completed | Iressa Expanded Access Program (EAP) NCT00034879 | AstraZeneca | Phase 3 |
| Completed | Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa NCT03977818 | Institut Bergonié | — |
| Completed | ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer NCT00034463 | Eli Lilly and Company | Phase 1 |